Enduring Material

• Diagnose the cause (e.g., Alzheimer’s, vascular dementia) and treat effectively.
• Leverage new tools in O2 to streamline care, improve efficiency, and meet best practices.
• Detect cognitive changes early and define the stage (SCI, MCI, or dementia).

• The University of Kansas Medical Center designates this enduring material for a maximum of 0.25 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
• The University of Kansas Medical Center designates this activity for a maximum of 0.25 ANCC contact hours. Nurses should claim only the credit commensurate with the extent of their participation in the activity.

This brief, focused microlearning session explores emerging amyloid-based biomarkers. Participants will learn when and how to order these tests, interpret results, communicate findings, and evaluate therapeutic implications and limitations of blood biomarkers.

Jeffrey Burns, MD, Professor, Department of Neurology has disclosed a financial relationship with one or more ineligible companies whose primary business is producing, marketing, selling, re-selling, or distributing healthcare products used by or on patients:

• Eli Lilly - Consulting - Relationship Has Not Ended
• Eisai - Consulting - Relationship Has Not Ended
• Renew Research - Consulting - Relationship Has Not Ended
• Labcorp - Consulting - Relationship Ended
• Roche - Consulting - Relationship Ended
• Abbvie - Consulting - Relationship Ended
• Novo Nordisk - Consulting - Relationship Ended
• Eli Lilly - Speaking - Relationship Has Not Ended

Any financial relationship that was found to be relevant has been mitigated.

Ryan Townley, MD, Alzheimer's Clinical Trials Consortium Associate PI; Cognitive and Behavioral Fellowship Program Director; Assistant Professor, Eric Vidoni, PT, PhD, Timothy Ryan Smith, MD, Janell Jones, MD, and Lindsey Gillen, MSN, ARNP have no financial relationship(s) with ineligible companies whose primary business is producing, marketing, selling, re-selling, or distributing healthcare products used by or on patients to disclose.

Jeffrey Burns, MD, Professor, Department of Neurology has disclosed a financial relationship with one or more ineligible companies whose primary business is producing, marketing, selling, re-selling, or distributing healthcare products used by or on patients:

• Eisai - Consulting - Relationship Has Not Ended
• Eli Lilly - Consulting - Relationship Has Not Ended
• Labcorp - Consulting - Relationship Has Not Ended
• Roche - Consulting - Relationship Has Not Ended
• Renew Biotechnologies - Consulting - Relationship Has Not Ended
• Abbvie - Consulting - Relationship Has Not Ended
• Novo Nordisk - Consulting - Relationship Has Not Ended
• Intra-Cellular Therapies, Inc. - Data Monitoring Committee - Relationship Has Not Ended

Jennifer Woodward, MD, MPH has disclosed a financial relationship with one or more ineligible companies whose primary business is producing, marketing, selling, re-selling, or distributing healthcare products used by or on patients:

• Lilly - Consulting - Relationship Has Not Ended

Any financial relationship that was found to be relevant has been mitigated.

100 %

100 %

4/23/2025